Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan (Imitrex) in Healthy Subjects

Next Previous
Search
Trial Profile

Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan (Imitrex) in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Erenumab (Primary) ; Sumatriptan
  • Indications Migraine
  • Focus Pharmacodynamics
  • Sponsors Amgen

Most Recent Events

  • 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology
  • 28 Apr 2017 Results assessing effect of sumatriptan alone and in combination with erenumab on resting blood pressure and results of post hoc analysis assessing change in MAP following erenumab and sumatriptan alone, presented at the 69th Annual Meeting of the American Academy of Neurology
  • 09 Sep 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top